

# "Natural Approaches to Psoriasis: Unlocking the Healing Power of Boswellia and Beyond"

Anurag Yadav\*<sup>1</sup>, Neelam Jain<sup>2</sup>, Zufnoon Khan<sup>2</sup>, Mohd Faijan Mansoori<sup>3</sup>

<sup>1\*</sup>Research Scholar, Faculty of Pharmaceutical Sciences, Rama University, Kanpur- 209217, Uttar Pradesh, India

<sup>2</sup>Faculty of Pharmaceutical Sciences, Rama University, Kanpur- 209217, Uttar Pradesh, India

<sup>3</sup>Azad institute of pharmacy and research, Dr. A.P.J. Abdul Kalam Technical University Lucknow -226002

Date of Submission: 10-03-2025

Date of Acceptance: 20-03-2025

## ABSTRACT

Psoriasis is a chronic autoimmune skin disorder characterized by erythema, scaling, and epidermal hyperplasia. Conventional treatments, including corticosteroids and immunosuppressive agents, often present significant side effects. In this context, *Boswellia serrata*, a traditional medicinal plant known for its anti-inflammatory and immunomodulatory properties, has emerged as a promising natural alternative. This review explores the antipsoriatic potential of *Boswellia serrata* ethanolic extract, emphasizing its pharmacological mechanisms, experimental evidence in Wistar rat models, and therapeutic relevance.

**Keywords:** Psoriasis, Natural remedies, *Boswellia serrata*, Anti-inflammatory, Holistic treatments, Immunomodulatory, Herbal medicine, Turmeric (Curcumin).

## I. INTRODUCTION

Psoriasis is primarily driven by immune dysregulation, involving an interplay between the innate and adaptive immune systems. An estimated 2–4% of people worldwide suffer with psoriasis, a persistent, immune-mediated dermatological disorder [1]. Geographic heterogeneity is evident in the syndrome, with lower prevalence rates in East Asia (<1%) and sub-Saharan Africa and greater prevalence rates recorded in nations like Norway (11.4%) and the United States (2.5–3.5%) [2]. Although there are two typical peaks of beginning for the disease, one occurs in early adulthood (15–25 years) and the other in later adulthood (50–60 years) [3]. Given that psoriasis is more prevalent in people with a family history of the condition, a genetic predisposition plays a key role [4].

According to Pathogenesis (2019), it is characterized by ongoing inflammation that leads to unchecked keratinocyte proliferation and differentiation[5]. According to the International Psoriasis Day Collaboration, 125 million people

worldwide—roughly 2-3% of the population—have psoriasis[6].

Research indicates that 10–30% of people with psoriasis also have psoriatic arthritis. This negatively impacts the quality of life for people with psoriasis[7,8]. The pathogenesis of psoriasis is yet unknown, however, because T-helper cells are present in the psoriatic state, it is believed to be a T-cell-triggered illness[9].

The two clinical types of psoriasis are inverse psoriasis, guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, and chronic plaque psoriasis (psoriasis vulgaris) [10]. Eighty to ninety percent of psoriasis patients have chronic psoriasis vulgaris. Erythematous, well-defined plaques covered with silvery scales are indicative of psoriasis vulgaris [11].

Itching and reddish, flaky skin patches covered with silver scales are the main symptoms of psoriasis [12]. Tiny scale regions, cracked skin, itching, soreness, corroded or swollen nails, genital and inflammatory sores, stiff joints, and excessive scalp dandruff are other symptoms [13].

Psoriasis is a complicated condition that is impacted by immunological, environmental, and hereditary factors[14].

There are 500–600 species of trees or shrubs, many with spines, in the 17 genera that make up the Burseraceae family. Many of them contain oils, gum resins, or latex, which can have a potent scent.

This family is found in all tropical climates and even the subtropics. In arid lowland parts of Eastern Africa, it frequently makes up the majority of the flora. Several species in this family provide resins that are highly valuable commercially as raw materials for myrrh, balm, and incense[15]. Trees or shrubs are *Boswellia* species. About 75% of the species in the genus *Boswellia* Roxb. Ex Colber (1807) are indigenous in North-East Africa. One species is found in Madagascar, and there are about

20 species known to exist in the arid regions of tropical Africa and India[15].

When cut, *Boswellia* trees release a gum resin that can be collected by scraping the tree's bark[16]. The pure white resin of *Boswellia* trees is either scraped off the tree with an iron tool or gathered on palm mats on the ground as it drips off in Oman, where the trees are grown and cultivated. December marks the start of harvesting, which peaks in March and May[17].

### Pathogenesis

A prevalent inflammatory skin illness, psoriasis has a complicated pathogenesis that includes environmental exposures, immunological dysfunction, and a genetic component[18]. Numerous consequences, including as obesity, metabolic syndrome, heart disease, and psoriatic arthritis, are associated with it. Obesity exacerbates pre-existing psoriasis, may increase an individual's psoriasis severity, and seems to be a strong predictor of incident psoriasis[19].

It is an immune system-mediated hereditary skin condition. The pathomechanisms at play entail intricate interactions between the innate and systems that adapt. T cells use the cytokines released by dendritic cells, keratinocytes, and macrophages to communicate with these cells. Environmental causes include things like streptococcal infection, smoking, stress, obesity, and alcohol use[20]. Numerous problems, including as depression, cancer, and cardiovascular disease, are associated with psoriasis. Vitamin D mimics, corticosteroids, and mild to severe psoriasis and tazarotene were successful treatments. Numerous germs can actually cause this ailment, such as the increased levels of *Corynebacterium*, *Propionibacterium*, *Streptococcus*, and *Staphylococcus* in psoriatic skin[21].

However, in a different study, *Corynebacterium*, *Propionibacterium*, *Streptococcus*, and *Staphylococcus* were all on the rise whereas *Staphylococci* were much reduced in lesional skin when compared to healthy controls[22].




Fig. No. 1: Basic pathogenesis of psoriasis[23].

A chronic inflammatory skin condition, psoriasis is impacted by immunological, microbial, and genetic factors. According to a study, psoriatic lesions had lower amounts of *Staphylococci* than healthy skin. Nonetheless, psoriasis has been connected to viruses like the human papillomavirus (HPV) and fungus like *Candida albicans* and *Malassezia* & Notably, both healthy and psoriatic skin have high levels of *Malassezia* [24].

Th1 cytokines, such as interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF- $\alpha$ ), and interferon-gamma (IFN- $\gamma$ ), are the main drivers of the immune response in psoriasis and are increased in psoriatic lesions, but Th2 cytokines, such as IL-4, IL-5, and IL-10, are not. Furthermore, cytotoxic T-lymphocytes (TC1) and Th1 effector cells are identified as important participants in the disease pathogenesis because epidermal T cells in psoriasis vulgaris mostly generate type 1 cytokines (IFN- $\gamma$ ,

IL-2, and TNF- $\alpha$ ). Despite the fact that TNF- $\alpha$  and IFN- $\gamma$  do not directly promote keratinocyte proliferation, psoriasis is thus classified as a Th1-driven illness [25].

Additionally, the hypothalamus-pituitary axis, which is connected to obesity, insulin resistance, and hypertension, can be activated by IL-6 and other pro-inflammatory cytokines. According to IL-6 also increases the generation of C-reactive protein (CRP) in hepatocytes and, in conjunction with TNF- $\alpha$ , interferes with insulin

signaling, changing insulin sensitivity. In addition to causing inflammation on the skin, psoriasis also involves interactions between keratinocytes, innate and adaptive immune cells, and dermal vascular structures. Psoriasis has both autoimmune and autoinflammatory characteristics. In certain situations, T-cell-driven autoimmune responses contribute to the development of the illness, while in others, innate immune activation brought on by intrinsic danger signals or cytokines plays a part[26].

### Medicinal Plants Effective for Psoriasis Treatment

Plant Name	Active Compounds	Mechanisms Of Action	Mode Of Application	References
Boswellia serrata (Indian Frankincense)	Boswellic acids (AKBA, KBA)	Inhibits 5-LOX, COX, and NF- $\kappa$ B pathways, reducing inflammation; regulates keratinocyte proliferation	Oral supplements, Topical creams	Ammon (2006); Siddiqui (2011)[27]
Aloe vera	Aloin, Acemannan, Glycoproteins	Anti-inflammatory, immunomodulatory; accelerates wound healing and reduces erythema	Gel, Creams	Surjushe et al. (2008)[28]
Curcuma longa (Turmeric)	Curcumin	Inhibits NF- $\kappa$ B, TNF- $\alpha$ , IL-6; antioxidant and anti-inflammatory effects	Oral supplements, Topical paste	Heng et al. (2000)[29]
Nigella sativa (Black Seed)	Thymoquinone	Modulates immune response, inhibits inflammatory cytokines (IL-17, TNF- $\alpha$ )	Oil, Capsules	Salem (2005)[30]
Camellia sinensis (Green Tea)	Epigallocatechin gallate (EGCG)	Reduces oxidative stress, inhibits keratinocyte proliferation	Tea extracts, Creams	Katiyar (2011)[31]
Glycyrrhiza glabra (Licorice)	Glycyrrhizin, Liquiritigenin	Corticosteroid-like effects; reduces inflammation and itching	Topical creams, Oral decoctions	Fu et al. (2005)[32]
Silybum marianum (Milk Thistle)	Silymarin	Antioxidant, hepatoprotective, reduces inflammation	Oral capsules, Extracts	Omer et al. (2010)[33]
Mahonia aquifolium (Oregon Grape)	Berberine, Alkaloids	Inhibits keratinocyte hyperproliferation, reduces IL-8 expression	Creams, Extracts	Wananukul et al. (2013)[34]

#### Boswellia serrata

Indian frankincense, or *Boswellia serrata*, is a tree that is indigenous to both India and

Pakistan's Punjab region. Because of its anti-inflammatory qualities, its resin has long been utilized in Ayurvedic medicine. Its possible

medicinal uses have been investigated in recent scientific investigations, especially in inflammatory

diseases[35].



Fig. No. 2: *Boswellia serrata* plant parts [36]

**Plant Profile: *Boswellia serrata***

**Scientific Classification:**

**Kingdom:** Plantae

**Family:** Burseraceae

**Genus:** *Boswellia*

**Species:** *Boswellia serrata*

**The history and applications of *Boswellia* resin**

Several ancient manuscripts make reference to the resin of *Boswellia* species (also known as "frankincense" and "olibanum") (Figure 03). *Boswellia* resin was once valued by numerous cultures as a valuable commodity for bartering and trading, on par with gold and ivory[37].



Fig.No.3: *Boswellia* resin[38]

According to the Ebers Papyrus, frankincense, or *Boswellia* resin, has been used medicinally and ceremonially since 1500 BC[39]. It was known symbolically as the "tears of Horus" in ancient Egypt[38]. Its enormous trade, which

reached North Africa, China, and Rome, is described in Greek and Roman writings[40].

While Celsus (2nd century C.E.) suggested using frankincense to cure wounds, internal bleeding, and bruising when combined with leek juice, the first-century physician Dioscorides (Dioscorides, 1st century C.E.)[41] observed that it could cause madness. *Boswellia* resin was essential to Temple incense rituals in ancient Judea[42]. Some academics speculate that the drink provided to Jesus prior to his crucifixion may have contained frankincense, which was used to numb the senses of condemned criminals in wine, according to the Babylonian Talmud (3rd–6th centuries C.E.)[43].

The first-century physician Dioscorides observed that frankincense could cause insanity (Dioscorides, 1st century C.E.)[44], whereas Celsus (2nd century C.E.) suggested using it to heal internal bleeding, cuts, and bruises when combined with leek juice[41]. Temple incense rituals in ancient Judea relied heavily on *Boswellia* resin[42]. Some academics speculate that the drink provided to Jesus before to his crucifixion may have contained frankincense, as the Babylonian Talmud (3rd–6th centuries C.E.) claims that it was used in wine to numb the senses of condemned criminals[43].

In the 11th century, the Persian scholar Ibn Sina (Avicenna) documented *Boswellia*'s use for urinary tract infections, inflammation, and cognitive disorders like amnesia and amentia[45].

Beyond the Near East, *boswellia* resin is used for its purportedly psychotropic, anti-inflammatory, and wound-healing qualities. In the

Christian community, its application in the fourth or fifth century saw the rise of worship [8,9] Boswellia trees are native to Ethiopia, where they are thought to provide a calming effect [46].

There are numerous non-pharmaceutical uses for boswellia resin. These days, frankincense is frequently used as incense in Catholic Christian churches, along with other places of worship and secular customs. It is also a crucial part of toiletries and perfumes [47]. Boswellia resin is sold extensively as a dietary supplement.

### Active ingredients

Resins from *Boswellia* spp. have been found to contain over 200 chemicals [48]. The long-standing customs of treating patients using Boswellia resin. Numerous research teams that concentrated on boswellic acids successfully tested them for inflammatory disorders (Figure No. 4).

Nevertheless, in contrast to the results obtained, the use of crude extracts in assays linked to inflammation occasionally revealed biphasic potentiating/inhibitory effects. They are by refined components from these extracts [49], and a number of studies show that purified boswellic acids may not always be as active as boswellia resin. [50]




Fig. No. 4: Boswellic acid [51]

These findings imply that many ingredients influence the resin's anti-inflammatory activity.

Few components have been identified and extracted during the early research on the anti-inflammatory properties of Boswellia resin extracts. The triterpene boswellic acids, which are thought to be biomarkers of olibanum, and the diterpenes incensole (Figure 5) and isoincensole, as well as their oxide or acetate derivatives, were identified as some of the main constituents of the resin [52].




Fig. No. 5: The structures of incensole acetate (R = Ac) and incensole (R = H) [51]

The ubiquity of boswellic acids, pentacyclic triterpenoids present in boswellia resin, led to their early identification. The anti-inflammatory and cytotoxic qualities of these compounds, especially acetyl- $\beta$ -boswellic acid (AbBA), 11-keto- $\beta$ -boswellic acid, and acetyl-11-keto- $\beta$ -boswellic acid (AKBA), have been thoroughly investigated [53].  $\beta$ -configured compounds are more efficacious than their  $\alpha$ -isomers, according to studies. Studies have also verified that these substances are present in human plasma following administration of extracts from Boswellia resin, indicating a certain degree of bioavailability. Extracting these chemicals from various Boswellia sources has been done using a variety of solvents, such as methanol, ethanol, and acetone [54].

### Boswellic acid's mode of action in treating psoriasis

*Boswellia serrata*'s active ingredients, especially boswellic acids, are primarily responsible for its medicinal promise in treating psoriasis. It has been demonstrated that these substances alter inflammatory pathways that are essential to the pathophysiology of psoriasis.

### Inhibition of Pro-Inflammatory Cytokines:

According to computational calculations, frankincense's diterpenoids and triterpenoids may be able to target important cytokines that aggravate psoriasis, such as interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF- $\alpha$ ). These cytokines are essential to the inflammatory mechanisms that underlie psoriasis [55][56].

**Signaling Pathway Modification:** Boswellic acids may have an impact on important signaling pathways related to inflammation. According to in

silico research, these substances have the ability to impact pathways like nitric oxide synthase (NOS) and Janus kinase (JAK), which are linked to the inflammatory response linked to psoriasis[56].

**Anti-inflammatory Effects:** The main way that BAs reduce inflammation is by blocking important enzymes that are involved in the production of inflammatory mediators. They specifically block the cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways, which lowers the generation of prostaglandin and leukotriene, two essential components of the inflammatory cascade linked to psoriasis. The inflammatory reactions that are typical of psoriatic lesions are lessened by this dual inhibition [57].

**Immunomodulatory Activity:** Acetyl-11-keto- $\beta$ -boswellic acid (AKBA) stands out among the other BAs due to its immunomodulatory qualities. By inhibiting the nuclear factor-kappa B (NF- $\kappa$ B) signaling pathway, AKBA reduces the synthesis of pro-inflammatory cytokines such interleukin-6 (IL-6), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF- $\alpha$ ). These cytokines are essential to the pathophysiology of psoriasis, and reducing their expression helps to lessen the symptoms of the condition [58].

**Regulation of Keratinocyte Proliferation:** The hallmark of psoriasis is keratinocyte hyperproliferation, which results in thicker skin plaques. According to studies, BAs may reduce epidermal hyperplasia by modifying keratinocyte development. Normalizing skin cell turnover and reducing skin thickness and scaling linked to psoriatic lesions are two benefits of this modulation [59].

**Antioxidant Properties:** One important factor in the pathophysiology of psoriasis is oxidative stress. Strong antioxidant activity is exhibited by BAs, which neutralize reactive oxygen species and lessen oxidative damage to skin cells. BAs help reduce inflammation and cellular damage in psoriatic skin by reducing oxidative stress.[60]

#### **Boswellia serrata's effects on various illnesses**

##### **Osteoarthritis & Rheumatoid Arthritis**

**Action:** Reduces cartilage breakdown, enhances joint function, and inhibits pro-inflammatory enzymes(5-lipoxygenase).

**Effectiveness:** Research indicates that there is less discomfort, stiffness, and increased mobility.[61]

##### **Inflammatory Bowel Disease (IBD)(Ulcerative Colitis, Crohn's Disease)**

**Action:** Promotes gut healing, lowers intestinal inflammation, and lowers leukotriene synthesis.

**Effectiveness:** Research indicates symptom improvements that are on par with those of common therapies like mesalazine.[62]

##### **Asthma & Respiratory Disorders**

**Action:** Improves lung function, lowers airway inflammation, and decreases leukotrienes that cause bronchoconstriction.

**Effectiveness:** Studies show that asthma symptoms are lessened and breathing ability is enhanced.[63]

##### **Cancer**

**Action:** Induces apoptosis, inhibits angiogenesis, and modulates the immune system to exhibit anti-tumor actions.

**Effectiveness:** More research is required, however some studies indicate promise in the treatment of pancreatic cancer, breast cancer, and brain tumors (glioblastomas).[64]

##### **Neurological Disorders (Alzheimer's, Multiple Sclerosis)**

**Action:** Protects neurons, lowers neuroinflammation, and may prevent the development of amyloid plaque.

**Effectiveness:** Initial research suggests possible advantages for neuroprotection and cognitive function.[65]

##### **Cardiovascular Diseases**

**Action:** Enhances endothelial function, lowers cholesterol, and lessens inflammation.

**Effectiveness:** Additional study is required, but some studies point to a cardioprotective role.[66]

##### **Diabetes & Metabolic Disorders**

**Action:** Reduces oxidative stress, enhances insulin sensitivity, and lowers blood glucose.

**Effectiveness:** Research points to decreased complications from diabetes and better glycemic control.[67]

## **II. FUTURE PERSPECTIVES**

Research on the mechanisms underlying psoriasis, standardization, and integration with contemporary medicine are key to the future of natural treatments for the condition, especially the usage of *Boswellia serrata*. To determine its specific therapeutic effect, future research should concentrate on clarifying the molecular pathways via which boswellic acids control inflammation, especially within the NF- $\kappa$ B, JAK-STAT, and IL-23/Th17 axes. Bioavailability and efficacy will be increased by standardizing *Boswellia* extracts and developing better drug delivery methods such liposomes, nanoparticles, and transdermal

formulations. Its therapeutic efficacy, ideal dosage, and long-term safety must be confirmed by extensive randomized controlled trials (RCTs). Future studies will examine how *Boswellia* interacts with the microbiota to control systemic inflammation, as the gut-skin axis has also been a major focus of interest. Personalized medicine breakthroughs using genetic

### III. CONCLUSION

Compared to traditional medications, natural therapies—especially *Boswellia serrata*—offer promising opportunities for psoriasis management with fewer adverse effects. People with psoriasis may have improved symptom management and general well-being by combining herbal therapy, dietary changes, and lifestyle adjustments. Integrating these natural methods into evidence-based dermatological care will require more study and clinical validation.

#### Author Contributions:

The author conceptualized, researched, and drafted the manuscript. They performed a comprehensive review of the literature, synthesized relevant findings, and contributed to the critical analysis of the topic. Additionally, the author revised and finalized the article for publication, ensuring clarity and accuracy.

#### Acknowledgments

The authors would like to thank all of the co-authors for their continued support and advice.

#### Conflict of Interest

The authors hereby declare that they have no conflict of interest.

### REFERENCES

- [1]. Elder, J. T., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Stuart, P. E., Tejasvi, T., Nair, R. P. (2001). Molecular dissection of psoriasis: Integrating genetics and biology. *The Journal of Investigative Dermatology*, 117, 1335-1341.
- [2]. Michalek, I. M., Loring, B., & John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. *Journal of the European Academy of Dermatology and Venereology*, 31(2), 205-212.
- [3]. Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. *New England Journal of Medicine*, 361(5), 496-509.
- [4]. Parisi, R., Symmons, D. P., Griffiths, C. E., & Ashcroft, D. M. (2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. *Journal of Investigative Dermatology*, 133(2), 377-385.
- [5]. Nickoloff, B. J., & Nestle, F. O. (2014). *Pathogenesis and Treatment of Psoriasis*. Springer Science & Business Media.
- [6]. Griffiths, C. E. M., Barker, J. N. W. N., & Bleiker, T. (2016). *Rook's Textbook of Dermatology* (9th ed.). Wiley-Blackwell.
- [7]. Gladman, D. D., Chandran, V. (2010). *Psoriatic Arthritis*. Oxford University Press.
- [8]. Lebwohl, M., Heymann, W. R., Berth-Jones, J., Coulson, I. (2013). *Treatment of Skin Disease: Comprehensive Therapeutic Strategies*. Elsevier Health Sciences.
- [9]. Krueger, J. G., Bowcock, A. (2005). *Psoriasis: Pathophysiology, Clinical Features, and Therapy*. CRC Press.
- [10]. Griffiths, C. E. M., Barker, J. N. W. N., Bleiker, T., Chalmers, R., Creamer, D. (2016). *Rook's Textbook of Dermatology* (9th ed.). Wiley-Blackwell.
- [11]. Krueger, J. G., Bowcock, A. M. (2005). *Psoriasis: Pathophysiology, Clinical Features, and Therapy*. CRC Press.
- [12]. Griffiths, C. E. M., Barker, J. N. W. N., Bleiker, T., Chalmers, R., Creamer, D. (2016). *Rook's Textbook of Dermatology* (9th ed.). Wiley-Blackwell.
- [13]. Lebwohl, M., Heymann, W. R., Berth-Jones, J., Coulson, I. (2013). *Treatment of Skin Disease: Comprehensive Therapeutic Strategies* (4th ed.). Elsevier Health Sciences.
- [14]. Krueger, J. G., Bowcock, A. M. (2005). *Psoriasis: Pathophysiology, Clinical Features, and Therapy*. CRC Press.
- [15]. Vollesen K. In: Hedberg I, Eduards S. (eds) *Flora of Ethiopia*. Ethiopia: Addis Ababa and Asmara, 1989: 442-446.
- [16]. Michie CA, Cooper E. Frankincense and myrrh as remedies in children. *J R Soc Med* 1991; 84: 602-605.
- [17]. Marshall S. Frankincense: festive pharmacognosy. *Pharm J*. 2003; 271: 862-864.
- [18]. John Y. M. Koo, Ethan C. Levin, Mark G. Lebwohl. CRC Press. 2014.
- [19]. Kenneth B. Gordon, Eric M. Ruderman. Springer. 2005

- [20]. Clinical Reviews in Allergy & Immunology. 2024
- [21]. John Y. M. Koo, Ethan C. Levin, Mark G. Lebwohl. CRC Press. 2014
- [22]. Bryan Tunland. Academic Press. 2018
- [23]. Omali Y. Elkhawaga, Mohamed M. Ellety, Sheref O. Mofty, Mohamed S. Ghanem, Abdallah O. Mohamed. Review of natural compounds for potential psoriasis treatment. *Inflammopharmacology*. 2023. 31:1183–1198.
- [24]. Blauvelt, A., &Chiricozzi, A. (2018). The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. *Clinical Reviews in Allergy & Immunology*, 55(3), 379–390.
- [25]. Spa F (2008) Inflammation in atherosclerosis and psoriasis: commonpathogenic mechanisms and the potential for an integrated treatmentapproach, vol 159, pp 10–17.
- [26]. Meglio, P. D., Villanova, F., & Nestle, F. O. (2014). Psoriasis. *Nature Reviews Disease Primers*, 1(1), 150-165.
- [27]. Ammon, H. P. T. (2006). Boswellic acids in chronic inflammatory diseases. *Planta Medica*, 72(12), 1100–1116.
- [28]. Surjushe, A., Vasani, R., &Saple, D. G. (2008). Aloe vera: a short review. *Indian Journal of Dermatology*, 53(4), 163–166.
- [29]. Heng, M. C., Song, M. K., Harker, J., & Heng, M. K. (2000). Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical,histological and immunohistochemical parameters. *British Journal of Dermatology*, 143(5), 937–949.
- [30]. Salem, M. L. (2005). Immunomodulatory and therapeutic properties of the *Nigella sativa* L. seed. *International Immunopharmacology*, 5(13-14), 1749–1770.
- [31]. Katiyar, S. K. (2011). Green tea prevents non-melanoma skin cancer by enhancing DNA repair. *Archives of Biochemistry and Biophysics*, 508(2), 152–158.
- [32]. Fu, Y., Hsieh, T. C., Guo, J., Kunicki, J., Lee, M. Y., Darzynkiewicz, Z., & Wu, J. M. (2005). Licochalcone-A, a novel flavonoid isolated from licorice root (*Glycyrrhiza glabra*), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. *Biochemical and Biophysical Research Communications*, 322(1), 263–270.
- [33]. Omer, S. A., Al-Daghri, N. M., Al-Okail, M. S., Al-Attas, O. S., & Al-Ajlan, A. S. (2010). Low bone mineral density and its associated factors in premenopausal and postmenopausal Arab women. *Osteoporosis International*, 21(9), 1613–1620.
- [34]. Wananukul, S., Chatproedprai, S., &Tempark, T. (2013). Topical Mahonia aquifolium for treating recalcitrant psoriasis in children. *Pediatric Dermatology*, 30(5), 587–590.
- [35]. Roy, S., Khanna, S., Krishnaraju, A. V., et al. (2011). Boswellia Serrata, A Potential Antiinflammatory Agent: An Overview. *Indian Journal of Pharmaceutical Sciences*, 73(3), 255–261.
- [36]. <https://www.medicoverhospitals.in/diseases/psoriasis/>
- [37]. Michie CA, Cooper E. Frankincense and myrrh as remedies in children. *J R Soc Med* 1991; 84: 602–605.
- [38]. Arieh Moussaieffa and Raphael Mechoulamb, *Journal of Pharmacy and Pharmacology (JPP 2009)*, 61: 1281–1293 \_ 2009 The Authors , ISSN 0022-3573
- [39]. Michie CA, Cooper E. Frankincense and myrrh as remedies in children. *J R Soc Med* 1991; 84: 602–605.
- [40]. Van Beek, T. A., & Scheen, A. J. (2017). Frankincense – Traditional Use and Modern Applications. *Phytotherapy Research*, 31(2), 233–244.
- [41]. Celsus, A. C. (2nd century C.E.). *De Medicina*. Harvard University Press.
- [42]. Gafni, I. (2001). *The Jews of Talmudic Babylonia: A Social and Cultural History*. Johns Hopkins University Press.
- [43]. Neusner, J. (1994). *The Babylonian Talmud: Its Origin and Meaning*. Brill.
- [44]. Dioscorides, P. (1st century C.E.). *De Materia Medica*. Translated by Osbaldeston& Wood.
- [45]. Avicenna, I. (1025). *The Canon of Medicine*. Translated by G. Bos, Oxford University Press.
- [46]. Getahon A. *Some Common Medicinal and Poisonous Plants Used in Ethiopian Folkmedicine*, Mimeographed. Addis Ababa: Addis Ababa University, 1976.



- [47]. Michie CA, Cooper E. Frankincense and myrrh as remedies in children. *J R Soc Med* 1991; 84: 602–605.
- [48]. Ammon HP. Boswellic acids in chronic inflammatory diseases. *Planta Med* 2006; 12: 1100–1116.
- [49]. Safayhi H et al. Concentration-dependent potentiating and inhibitory effects of *Boswellia* extracts on 5-lipoxygenase product formation in stimulated PMNL. *Planta Med* 2000; 66: 110–113
- [50]. Poeckel D, Werz O et al. Boswellic acids: biological actions and molecular targets. *Curr Med Chem* 2006; 13: 3359–3369.
- [51]. ArieH Moussaieffa and Raphael Mechoulamb, *Journal of Pharmacy and Pharmacology (JPP)* 2009, 61: 1281–1293 \_ 2009 The Authors , ISSN 0022-3573
- [52]. Hamm S et al. A chemical investigation by headspace SPME and GC-MS of volatile and semi-volatile terpenes in various olibanum samples. *Phytochemistry* 2005; 66: 1499–1514.
- [53]. Bu`chele B et al. Characterization of 3alpha-acetyl-11-ketoalpha-boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. *Planta Med* 2006; 72: 1285–1289.
- [54]. Winterstein A, Stein G. Untersuchungen in der Saponinreihe Zur Kenntnis der Mono-oxy-triterpensa`uren. *Hoppe-Seyler's Z Physiol Chem* 1932; 208: 9–25.
- [55]. B`uchele, B., Zugmaier, W., Genze, F., & Simmet, T. (2003). High-performance liquid chromatographic determination of pentacyclic triterpenes in human plasma after oral administration of *Boswellia serrata* extract. *Journal of Chromatography B*, 795(2), 355–362.
- [56]. Siddiqui, M. Z. (2011). *Boswellia serrata*, a potential antiinflammatory agent: an overview. *Indian Journal of Pharmaceutical Sciences*, 73(3), 255–261.
- [57]. Poeckel, D., & Werz, O. (2006). Boswellic acids: biological actions and molecular targets. *Current Medicinal Chemistry*, 13(28), 3359–3369.
- [58]. Ammon, H. P. T. (2006). Boswellic acids in chronic inflammatory diseases. *Planta Medica*, 72(12), 1100–1116.
- [59]. Tsai, Y.-C., Chang, H.-H., Chou, S.-C., Chu, T. W., Hsu, Y.-J., Hsiao, C.-Y., Lo, Y.-H., Wu, N.-L., Chang, D.-C., & Hung, C.-F. (2022). Evaluation of the Anti-Atopic Dermatitis Effects of  $\alpha$ -Boswellic Acid on TNF- $\alpha$ /IFN- $\gamma$ -Stimulated HaCaT Cells and DNCB-Induced BALB/c Mice. *International Journal of Molecular Sciences*, 23(17), 9863.
- [60]. Roy, A., Kulkarni, R., & Chandrasekaran, B. (2023). The journey of boswellic acids from synthesis to pharmacological applications: A comprehensive review. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 396(4), 567–589.
- [61]. Yu, G., Luo, H., Wu, Y., & Wu, J. (2020). Effectiveness of *Boswellia* and *Boswellia* extract for osteoarthritis patients: A systematic review and meta-analysis. *BMC Complementary Medicine and Therapies*, 20(1), 225.
- [62]. Gupta, I., Parihar, A., Malhotra, P., et al. (2001). Effects of gum resin of *Boswellia serrata* in patients with chronic colitis. *Planta Medica*, 67(5), 391-395.
- [63]. Gupta, I., Gupta, V., Parihar, A., et al. (1998). Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. *European Journal of Medical Research*, 3(11), 511-514.
- [64]. Poeckel, D., & Werz, O. (2006). Boswellic acids: biological actions and molecular targets. *Current Medicinal Chemistry*, 13(28), 3359-3369.
- [65]. Borrelli, F., & Izzo, A. A. (2009). The plant kingdom as a source of anti-inflammatory and anti-arthritic agents. *Phytotherapy Research*, 23(8), 1015-1021.
- [66]. Siddiqui, M. Z. (2011). *Boswellia serrata*, a potential antiinflammatory agent: an overview. *Indian Journal of Pharmaceutical Sciences*, 73(3), 255-261.
- [67]. Mazaheri, S., Moghaddam, A. B., & Haghghian, H. K. (2024). Effect of boswellia (*Boswellia serrata* L.) supplementation on glycemic markers and lipid profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Frontiers in Clinical Diabetes and Healthcare*, 5, 1466408.